How Remdesivir Moved From Back Shelf to Best Hope for Treating COVID-19
This study showed that a five-day regimen is as effective as 10 days–that’s important, doctors say, since it could mean shorter stays in the hospital, which could alleviate some of the burden on the health care system. “Of course we will have to wait for the final review of all the data, but it would be very nice to have an anti-viral that’s efficacious in this terrible illness,” says Dr. Aruna Subramanian, a clinical professor of medicine at Stanford and an investigator on the study. “At least we know that we can help patients with this, and that’s really the bottom line.” That optimism is still tempered with a sizable amount of caution, since researchers have outstanding and important questions about which patients might benefit most, and when in the course of a COVID-19 illness the drug will work best. The study begun in China, for example, did not find the same positive results among severely ill patients. In that study, people taking the drug did no better than those given a placebo. However, the researchers had to end that trial early because cases started to wane in China and they could not enroll enough people with advanced COVID-19; that means the results–despite being discouraging–may not be statistically significant. In any case, the results from the NIAID study were strong enough for the U.S. FDA to issue the emergency-use authorization so more sick patients might benefit from it. The NIAID study will als...
Authors: Rombauts A, Abelenda-Alonso G, Cuervo G, Gudiol C, Carratalà J Abstract INTRODUCTION: Despite adequate antibiotic coverage, community-acquired pneumonia (CAP) remains a leading cause of hospitalization and mortality worldwide. It induces both a local pulmonary and a systemic inflammatory response, particularly significant in severe cases. The intensity of the dysregulated host response varies from patient to patient and has a negative impact on survival and other outcomes. AREAS COVERED: This comprehensive review summarizes the pathophysiological aspects of the inflammatory response in CAP, brie...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Zhongyi Zhang, Wen-Xiong Wang, Nengjian Zheng, Yansheng Cao, Hongwei Xiao, Renguo Zhu, Hui Guan, Huayun Xiao
Publication date: Available online 10 October 2020Source: Meta GeneAuthor(s): Mansour Zamanpoor, Hamid Ghaedi, Mir Davood Omrani
Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Shreeram Akilesh, Cynthia C. Nast, Michifumi Yamashita, Kammi Henriksen, Vivek Charu, Megan L. Troxell, Neeraja Kambham, Erika Bracamonte, Donald Houghton, Naila I. Ahmed, Chyi Chyi Chong, Bijin Thajudeen, Shehzad Rehman, Firas Khoury, Jonathan E. Zuckerman, Jeremy Gitomer, Parthassarathy C. Raguram, Shanza Mujeeb, Ulrike Schwarze, M. Brendan Shannon
CONCLUSIONS: Xyloglucan/gelose plus ORS was effective and safe in treating acute diarrhea in children. PMID: 33028102 [PubMed - as supplied by publisher]
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
CONCLUSIONS: This single practice study showed total patient contact was similar over both sample periods, but most contact in 2020 was virtual. Further longitudinal multi-practice studies to confirm these findings and describe future consultation patterns are needed to inform general practice service delivery post-COVID-19. PMID: 33032304 [PubMed - in process]
Publication date: Available online 1 October 2020Source: Academic RadiologyAuthor(s): Neo Poyiadji, Chad Klochko, Jeff LaForce, Manuel L. Brown, Brent Griffith
Curious what people think with pandemic and lack of away rotations.
Publication date: 15 February 2021Source: Personality and Individual Differences, Volume 170Author(s): Brian W. Haas, Fumiko Hoeft, Kazufumi Omura
More News: Acetaminophen | Allergy | Allergy & Immunology | Arthritis | Bird Flu | Cardiology | Centers for Disease Control and Prevention (CDC) | China Health | Clinical Trials | Computers | Coronavirus | Cough | COVID-19 | Department of Health | Ebola | Emergency Medicine | ENT & OMF | Eyes | Flu Pandemic | Food and Drug Administration (FDA) | Government | H5N1 | Health | Health Management | Heart | Hospitals | Infectious Diseases | Influenza | Insomnia | International Medicine & Public Health | Japan Health | Learning | Lortab | Medical Ethics | MERS | National Institute for Health and Clinical Excelle | Nurses | Nursing | Outbreaks | Pandemics | Pneumonia | Respiratory Medicine | Rheumatoid Arthritis | Rheumatology | SARS | Science | South Korea Health | Statistics | Study | Thailand Health | Training | Universities & Medical Training | WHO | X-Ray